thalidomide has been researched along with Pulmonary Fibrosis in 11 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, the potential effects of thalidomide (Thal) on bleomycin (BLM)-induced pulmonary fibrosis were investigated." | 7.85 | Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts. ( Chen, M; Dong, X; Fan, Q; Li, M; Li, X; Wei, W, 2017) |
| "Silicosis is the most prevalent occupational disease in China." | 5.72 | Thalidomide Alleviates Pulmonary Fibrosis Induced by Silica in Mice by Inhibiting ER Stress and the TLR4-NF-κB Pathway. ( Cai, W; Jin, F; Li, T; Li, Y; Liu, H; Liu, W; Wang, X; Xu, H; Yang, F; Yang, X, 2022) |
| "Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis." | 5.34 | Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. ( Hisamori, S; Kadokawa, Y; Kubo, H; Mishima, M; Nakano, T; Tabata, C; Tabata, R; Takahashi, M, 2007) |
| "To evaluate the immune regulatory and anti-fibrosis function of thalidomide (Thal) in systemic sclerosis (SSc), we investigated the effects of Thal on: (a) Th17 and Treg cell production; (b) related factors expression; and (c) transforming growth factor (TGF)-β1/Smad3 pathway, using a mouse model of SSc." | 3.96 | Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis. ( Lei, L; Li, X; Lu, Y; Tao, Z; Wen, J; Zhao, C; Zheng, L, 2020) |
| "Pomalidomide, previously used to treat multiple myeloma, has been reported to cause acute pulmonary toxicity that improves with drug discontinuation." | 3.88 | Pulmonary toxicity associated with pomalidomide. ( Blanc, PD; Brown, JK; Callahan, EC; Elicker, B; Gajic, S; Ley, B, 2018) |
| "In this study, the potential effects of thalidomide (Thal) on bleomycin (BLM)-induced pulmonary fibrosis were investigated." | 3.85 | Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts. ( Chen, M; Dong, X; Fan, Q; Li, M; Li, X; Wei, W, 2017) |
| "Silicosis is the most prevalent occupational disease in China." | 1.72 | Thalidomide Alleviates Pulmonary Fibrosis Induced by Silica in Mice by Inhibiting ER Stress and the TLR4-NF-κB Pathway. ( Cai, W; Jin, F; Li, T; Li, Y; Liu, H; Liu, W; Wang, X; Xu, H; Yang, F; Yang, X, 2022) |
| "Thalidomide (THD) has a therapeutic effect on fibrotic and inflammatory disorders." | 1.48 | Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. ( Bian, C; Chen, J; Qin, WJ; Wang, YY; Zhang, CY; Zhao, R; Zhe, H; Zhu, YZ; Zou, GL, 2018) |
| "Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis." | 1.34 | Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. ( Hisamori, S; Kadokawa, Y; Kubo, H; Mishima, M; Nakano, T; Tabata, C; Tabata, R; Takahashi, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Cai, W | 1 |
| Jin, F | 1 |
| Wang, X | 1 |
| Liu, W | 1 |
| Li, T | 1 |
| Yang, X | 1 |
| Liu, H | 1 |
| Xu, H | 1 |
| Yang, F | 1 |
| Finato, AC | 1 |
| Almeida, DF | 1 |
| Dos Santos, AR | 1 |
| Nascimento, DC | 1 |
| Cavalcante, RS | 1 |
| Mendes, RP | 1 |
| Soares, CT | 1 |
| Paniago, AMM | 1 |
| Venturini, J | 1 |
| Lu, Y | 1 |
| Zhao, C | 1 |
| Lei, L | 1 |
| Tao, Z | 1 |
| Zheng, L | 1 |
| Wen, J | 1 |
| Li, X | 2 |
| Zheng, F | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Fu, Y | 1 |
| Lin, Z | 1 |
| Dong, X | 1 |
| Li, M | 1 |
| Chen, M | 1 |
| Fan, Q | 1 |
| Wei, W | 1 |
| Bian, C | 1 |
| Qin, WJ | 1 |
| Zhang, CY | 1 |
| Zou, GL | 1 |
| Zhu, YZ | 1 |
| Chen, J | 1 |
| Zhao, R | 1 |
| Wang, YY | 1 |
| Zhe, H | 1 |
| Gajic, S | 1 |
| Callahan, EC | 1 |
| Brown, JK | 1 |
| Elicker, B | 1 |
| Ley, B | 1 |
| Blanc, PD | 1 |
| Horton, MR | 1 |
| Danoff, SK | 1 |
| Lechtzin, N | 1 |
| Choe, JY | 1 |
| Jung, HJ | 1 |
| Park, KY | 1 |
| Kum, YS | 1 |
| Song, GG | 1 |
| Hyun, DS | 1 |
| Park, SH | 1 |
| Kim, SK | 1 |
| Subbian, S | 1 |
| Tsenova, L | 1 |
| O'Brien, P | 1 |
| Yang, G | 1 |
| Koo, MS | 1 |
| Peixoto, B | 1 |
| Fallows, D | 1 |
| Zeldis, JB | 1 |
| Muller, G | 1 |
| Kaplan, G | 1 |
| Tabata, C | 1 |
| Tabata, R | 1 |
| Kadokawa, Y | 1 |
| Hisamori, S | 1 |
| Takahashi, M | 1 |
| Mishima, M | 1 |
| Nakano, T | 1 |
| Kubo, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Pomalidomide in the Treatment of Refractory Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study[NCT01135199] | Phase 2 | 0 participants (Actual) | Interventional | 2010-04-30 | Withdrawn (stopped due to FDA did not accept sponsor's animal toxicology data to support proposed dosing.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thalidomide and Pulmonary Fibrosis
| Article | Year |
|---|---|
Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis.
Topics: Antitussive Agents; Cough; Humans; Prospective Studies; Pulmonary Fibrosis; Thalidomide | 2008 |
10 other studies available for thalidomide and Pulmonary Fibrosis
| Article | Year |
|---|---|
Thalidomide Alleviates Pulmonary Fibrosis Induced by Silica in Mice by Inhibiting ER Stress and the TLR4-NF-κB Pathway.
Topics: Animals; Mice; NF-kappa B; Pulmonary Fibrosis; Silicon Dioxide; Silicosis; Thalidomide; Toll-Like Re | 2022 |
Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis.
Topics: Animals; Antifungal Agents; Azithromycin; Cytokines; Disease Models, Animal; Drug Therapy, Combinati | 2020 |
Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
Topics: Animals; Cytokines; Disease Models, Animal; Female; Fibrosis; Hydroxyproline; Immunosuppressive Agen | 2020 |
Thal protects against paraquat-induced lung injury through a microRNA-141/HDAC6/IκBα-NF-κB axis in rat and cell models.
Topics: Animals; Apoptosis; Cell Line; Disease Models, Animal; Female; Histone Deacetylase 6; Inflammation M | 2021 |
Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Fibroblasts; Humans; Inflammation; | 2017 |
Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner.
Topics: A549 Cells; Animals; Cell Line, Tumor; Epithelial Cells; Female; Gene Expression Regulation; Humans; | 2018 |
Pulmonary toxicity associated with pomalidomide.
Topics: Antineoplastic Agents; Humans; Lung; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pulmonary Fibro | 2018 |
Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice.
Topics: Angiogenesis Inhibitors; Animals; Bleomycin; Cells, Cultured; Disease Models, Animal; Dose-Response | 2010 |
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.
Topics: Animals; Antitubercular Agents; Blotting, Western; Colony-Forming Units Assay; Cyclic Nucleotide Pho | 2011 |
Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice.
Topics: Animals; Bleomycin; Cell Differentiation; Cell Line; Cell Line, Transformed; Collagen Type I; Collag | 2007 |